Nanocarriers for Inner Ear Disease Therapy

Xu, Xiaoxiang; Zheng, Jie; He, Yanze; Lin, Kun; Li, Shuang; Zhang, Ya; Song, Peng; Zhou, Yuye; Chen, Xiong

doi:10.3389/fncel.2021.791573

Cited by 9 publications

(7 citation statements)

References 83 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Less-invasive techniques include intratympanic delivery [269] and the use of specific biomaterials such as hydrogel [270][271][272], gelfoam [250], and alginate beads [239], preventing the rapid flowing of the molecules through the Eustachian tube.…”

Section: Bdnf Protective Effects Against Hearing Lossmentioning

confidence: 99%

The Role of BDNF as a Biomarker in Cognitive and Sensory Neurodegeneration

Pisani

Paciello

Vecchio

et al. 2023

JPM

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) has a crucial function in the central nervous system and in sensory structures including olfactory and auditory systems. Many studies have highlighted the protective effects of BDNF in the brain, showing how it can promote neuronal growth and survival and modulate synaptic plasticity. On the other hand, conflicting data about BDNF expression and functions in the cochlear and in olfactory structures have been reported. Several clinical and experimental research studies showed alterations in BDNF levels in neurodegenerative diseases affecting the central and peripheral nervous system, suggesting that BDNF can be a promising biomarker in most neurodegenerative conditions, including Alzheimer’s disease, shearing loss, or olfactory impairment. Here, we summarize current research concerning BDNF functions in brain and in sensory domains (olfaction and hearing), focusing on the effects of the BDNF/TrkB signalling pathway activation in both physiological and pathological conditions. Finally, we review significant studies highlighting the possibility to target BDNF as a biomarker in early diagnosis of sensory and cognitive neurodegeneration, opening new opportunities to develop effective therapeutic strategies aimed to counteract neurodegeneration.

show abstract

Section: Bdnf Protective Effects Against Hearing Lossmentioning

confidence: 99%

The Role of BDNF as a Biomarker in Cognitive and Sensory Neurodegeneration

Pisani

Paciello

Vecchio

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…Due to their small size and theoretically endless possibilities for customization, nanoparticles have become an attractive option for drug delivery ( Table 1 ). The ability to customize nanoparticles is advantageous as size, charge, lipid solubility and membrane thickness strictly govern molecular passage across the RWM and these properties cannot be readily modified in most drugs ( Goycoolea and Lundman, 1997 ; Valente et al, 2017 ; Xu et al, 2021a ; Xu et al, 2021b ). Nanoparticles of sizes between 10 and 640 nm have been demonstrated to diffuse across the RWM, however most studies concur that sizes below 200 nm display the greatest permeation ( Valente et al, 2017 ; Xu et al, 2021a ; Chester et al, 2021 ).…”

Section: Novel Drug Delivery Systemsmentioning

confidence: 99%

Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear

Delaney,

Liew,

Lye

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Despite significant advances in the development of therapeutics for hearing loss, drug delivery to the middle and inner ear remains a challenge. As conventional oral or intravascular administration are ineffective due to poor bioavailability and impermeability of the blood-labyrinth-barrier, localized delivery is becoming a preferable approach for certain drugs. Even then, localized delivery to the ear precludes continual drug delivery due to the invasive and potentially traumatic procedures required to access the middle and inner ear. To address this, the preclinical development of controlled release therapeutics and drug delivery devices have greatly advanced, with some now showing promise clinically. This review will discuss the existing challenges in drug development for treating the most prevalent and damaging hearing disorders, in particular otitis media, perforation of the tympanic membrane, cholesteatoma and sensorineural hearing loss. We will then address novel developments in drug delivery that address these including novel controlled release therapeutics such as hydrogel and nanotechnology and finally, novel device delivery approaches such as microfluidic systems and cochlear prosthesis-mediated delivery. The aim of this review is to investigate how drugs can reach the middle and inner ear more efficiently and how recent innovations could be applied in aiding drug delivery in certain pathologic contexts.

show abstract

“…Aside from ocular delivery, cubosomes may be a potential carrier for drug loading to treat inner ear diseases [ 115 ]. Al-Mahallawi et al conducted an evaluation for both the in vitro and in vivo study of the management of otitis externa in rabbits using norfloxacin-loaded cubosomes [ 21 ].…”

Section: Therapeutics Applicationmentioning

confidence: 99%

Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems

Leu,

Teoh,

Ling

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Due to their distinctive structural features, lyotropic nonlamellar liquid crystalline nanoparticles (LCNPs), such as cubosomes and hexosomes, are considered effective drug delivery systems. Cubosomes have a lipid bilayer that makes a membrane lattice with two water channels that are intertwined. Hexosomes are inverse hexagonal phases made of an infinite number of hexagonal lattices that are tightly connected with water channels. These nanostructures are often stabilized by surfactants. The structure’s membrane has a much larger surface area than that of other lipid nanoparticles, which makes it possible to load therapeutic molecules. In addition, the composition of mesophases can be modified by pore diameters, thus influencing drug release. Much research has been conducted in recent years to improve their preparation and characterization, as well as to control drug release and improve the efficacy of loaded bioactive chemicals. This article reviews current advances in LCNP technology that permit their application, as well as design ideas for revolutionary biomedical applications. Furthermore, we have provided a summary of the application of LCNPs based on the administration routes, including the pharmacokinetic modulation property.

show abstract

Nanocarriers for Inner Ear Disease Therapy

Cited by 9 publications

References 83 publications

The Role of BDNF as a Biomarker in Cognitive and Sensory Neurodegeneration

The Role of BDNF as a Biomarker in Cognitive and Sensory Neurodegeneration

Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear

Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems

Contact Info

Product

Resources

About